Cervical Cancer, Immunochemotherapy
Conditions
Brief summary
Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.
Interventions
DRUGCamrelizumab combined with chemotherapy
Camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery
Sponsors
Women's Hospital School Of Medicine Zhejiang University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with cervical cancer staged FIGO2018 IIIC1p or IIIC2p after radical surgery; 2. Positive PD-L1 expression; 3. ECOG score ≤1
Exclusion criteria
1. Positive parametrium or surgical margin; 2. Incomplete radical surgery; 3. Residual target lesions; 4. Active autoimmune disease or autoimmune disease requiring systemic treatment; 5. Previous treatment with immune checkpoint inhibitors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3-year disease-free survival rate | from enrollment until the date of first documented recurrence or date of death from any cause, whichever came first, assessed up to 100 months |
Countries
China
Outcome results
None listed